吉非替尼对敲低联蛋白A7的HepG2细胞增殖的影响

Effect of Gefitinib on Proliferation of the Annexin A7 Knockdown HepG2 Cell

目的:探讨表皮生长因子受体抑制剂吉非替尼对敲低膜联蛋白A7后的人肝癌细胞株HepG2细胞增殖的影响,为肝癌的分子靶向治疗提供实验依据。方法:将细胞分为吉非替尼组、siRNA转染、siRNA转染+吉非替尼、转染阴性对照组和空白对照组,用脂质体转染法靶向将ANXA7的siRNA转染入Hep G2细胞,在转染后6h在siRNA转染组和siRNA转染组+吉非替尼组加入一定浓度的吉非替尼,加药后72h进行MTT实验以检测细胞增殖活力,从而计算增殖抑制率。结果:MTT检测得知,siRNA转染组、吉非替尼组和siRNA转染+吉非替尼组,对细胞增殖有明显的抑制作用,较对照组差别有统计学意义(P<0.05)。结论:吉非替尼对敲低ANXA7后的Hep G2细胞的增殖具有更为明显的抑制作用。

Objective： To explore the effect of EGFR inhibitor gefitinib on proliferation of the annexin A7 knockdown HepG2 cell,and to provide the evidence for potential molecular target therapy in the HCC clinical treatment. Method： The HepG2 cells were divided into gefitinib group,a siRNA transfection group,siRNA transfection combined gefitinib group,negative group and control group.The siRNA was transfected into HepG2 cells by lipofectamine transfection method. Six hours after transfection,added a certain concentration of gefitinib into siRNA transfection group and siRNA transfection combined gefitinib group. Seventy-two hours after adding gefitinib,MTT assay was used to detect proliferation activity,and calculation the cell proliferation inhibition rate. Result： MTT assay showed that proliferation of the group of siRNA transfection,gefitinib and siRNA transfection combined gefitinib decreased significantly（ P 0. 05）. Conclusion： Gefitinib can inhibit proliferation of ANXA7 knockdown HepG2 cells.